Global Autologous Cell Therapy Market is Likely to Grow at a CAGR Value of 7.70% by 2028

The global autologous cell therapy market size was worth USD 8,218.50 million in 2021 and is estimated to grow to USD 12,825.86 million by 2028, with a compound annual growth rate (CAGR) of around 7.70 percent during the forecast period. The report analyzes the autologous cell therapy market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the autologous cell therapy market.

Autologous cell therapy is a therapeutic intervention using stem cells, where a patient's stem cells are cultured and grown outside the body. The cells were then reintroduced into the same patient's body. This therapy carries fewer risks because the reintroduced cells are less likely to be rejected because they come from the same person.

Over the years, autologous cell therapy has been used to treat many chronic diseases such as various forms of cancer and even blood disorders such as thalassemia. The increase in the number of people suffering from serious diseases has given rise to the demand for autologous cell therapy, driving the growth of the global autologous cell therapy market. Autologous cell therapy poses a moderate complexity risk compared to other treatments, a key growth driver of the market. However, the high treatment cost of autologous cell therapy is holding back the growth of the autologous cell therapy market. However, this constraint can be lifted if there is State intervention [AT1] in reimbursement by health insurance.

The global autologous cell therapy market is segregated based on source, application, end-user, and region. By source, the market is divided into bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, and chondrocytes. The bone marrow array is estimated to achieve the highest CAGR during the forecast period. By application, the market is bifurcated into cancer, neurodegenerative diseases, wound healing, orthopedic, cardiovascular diseases, and autoimmune diseases. Over the forecast period, the cancer segment is also expected to grow at a remarkable rate during the forecast period. By end-user, the market is categorized into hospitals, clinics, and others. The hospitals category dominated the market in 2021.

It is estimated that North America will have the largest share in the global autologous cell therapy market in 2021. Due to many research and development centers and institutes in stem cell treatment, this region holds a significant market share worldwide. Of the top 8 universities in the world, five are based in the United States, including the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, the Harvard Stem Cell Institute at Harvard University, Yale Stem Cell Center and Stem Research Institute, and Cell Biology and Regenerative Medicine at Yale University. During the projected time, the market in the Asia Pacific is expected to increase, resulting in substantial revenue generation.

The growing investment by developers and consumers in education about modern medical therapies is expected to increase the revenue generated by emerging economies in the region. Several stem cell associations exist in Asian countries to ensure that research and development initiatives are coordinated and focused. In addition, patients from Western countries have been seen migrating to Asian countries for treatment, possibly due to these countries' more flexible legislative structures.

Key market players in the global autologous cell therapy market include Daiichi Sankyo Co. Ltd., Bayer AG, Takeda Pharmaceutical Co. Ltd., Holostem Terapie Avanzate Srl, Teva Pharmaceutical Industries Ltd., Vericel Corp., Brainstorm Cell Therapeutics Inc., Osiris Therapeutics Inc., Sumitomo Chemical Co. Ltd., and FUJIFILM Holdings Corp.

Recent developments:

• In May 2022, ViaCyte, Inc. partnered with SQZ Biotechnologies to develop and commercialize a research-only (RUO) microfluidic intracellular delivery system. The partnership will enable market participants to present new cell engineering data in hematopoietic stem cells using mRNA.
• In July 2021, Minovia Therapeutics, Ltd. and Astellas Pharma Inc. signed strategic partnerships and worldwide licensing agreements to research, develop, and commercialize new stem cell therapy programs for diseases caused by mitochondrial dysfunction. This partnership aims to stimulate the generation of allogeneic mitochondrial cell treatment programs. The two companies will jointly seek candidates for a cell therapy program that includes Astellas' proprietary genetically engineered induced pluripotent stem cells derived cells and complemented by platform technology.

Browse the full “Global Autologous Cell Therapy Market By Source (Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, and Chondrocytes), By Application (Cancer, Neurodegenerative Diseases, Wound Healing, Orthopedic, Cardiovascular Diseases, and Autoimmune Diseases), By End-user (Hospitals, Clinics, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/autologous-cell-therapy-market

The global autologous cell therapy market is segmented as follows:

By Source

• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Hematopoietic Stem Cells
• Chondrocytes

By Application

• Cancer
• Neurodegenerative Diseases
• Wound Healing
• Orthopedic
• Cardiovascular Diseases
• Autoimmune Diseases

By End-user

• Hospitals
• Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com